On August 14, 2020 AnHeart Therapeutics of Hangzhou reported that it raised over $20 million in an over-subscribed Series A+ financing round (Press release, AnHeart Therapeutics, AUG 14, 2020, View Source [SID1234563662]). The company will use the proceeds to support global Phase II trials of taletrectinib, a selective next-gen ROS1/NTRK inhibitor, along with advancing its other oncology assets. Because taletrectinib is capable of crossing the blood-brain barrier, it is expected to be effective against brain metastases in NSCLC. AnHeart will test the candidate in patients who have NSCLC with ROS1 mutations or advanced/metastatic solid tumors with NTRK mutations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!